Auteurs
Analysis
France
Racine
Analysis
France
Exploration
Accueil
Racine
Racine

Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « Christopher G. Goetz »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Christophe Verny < Christopher G. Goetz < Christopher Goetz  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 28.
[20-40] [0 - 20][0 - 28]
Ident.Authors (with country if any)Title
000306 (2008) Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Christina Sampaio [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Anxiety rating scales in Parkinson's disease: Critique and recommendations
000317 (2007) Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne]Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial
000327 (2007) Christopher G. Goetz [États-Unis] ; Stanley Fahn [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Matthew B. Stern [États-Unis] ; Barbara C. Tilley [États-Unis] ; Richard Dodel [Allemagne] ; Bruno Dubois [France] ; Robert Holloway [États-Unis] ; Joseph Jankovic [États-Unis] ; Jaime Kulisevsky [Espagne] ; Anthony E. Lang [Canada] ; Andrew Lees (neurologue) [Royaume-Uni] ; Sue Leurgans [États-Unis] ; Peter A. Lewitt [États-Unis] ; David Nyenhuis [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Anette Schrag [Royaume-Uni] ; Jeanne A. Teresi [États-Unis] ; Jacobus J. Van Hilten [Pays-Bas] ; Nancy Lapelle [États-Unis]Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
000342 (2007) Anette Schrag [Royaume-Uni] ; Paolo Barone [Italie] ; Richard G. Brown [Royaume-Uni] ; Albert F. G. Leentjens [Pays-Bas] ; William M. Mcdonald [États-Unis] ; Sergio Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Depression rating scales in Parkinson's disease: Critique and recommendations
000343 (2007) Emmanuel Broussolle [France] ; Paul Krack [France] ; Stéphane Thobois [France] ; Jing Xie-Brustolin [France] ; Pierre Pollak [France] ; Christopher G. Goetz [États-Unis]Contribution of Jules Froment to the study of Parkinsonian rigidity
000404 (2005) Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
000431 (2004) Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Carl Counsell [Portugal] ; Nir Giladi [Israël] ; Robert G. Holloway [États-Unis] ; Charity G. Moore [États-Unis] ; Gregor K. Wenning [Autriche] ; Melvin D. Yahr [États-Unis] ; Lisa Seidl [États-Unis]Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
000528 (2000) Stéphane Palfi [États-Unis] ; Liza Leventhal [États-Unis] ; Christopher G. Goetz [États-Unis] ; Philippe Hantraye [France] ; Ben-Zion Roitberg [États-Unis] ; Joe Sramek [États-Unis] ; Marina Emborg [États-Unis] ; Jeffrey H. Kordower [États-Unis]Delayed onset of progressive dystonia following subacute 3‐nitropropionic acid treatment in Cebus apella monkeys

List of associated KwdEn.i

Nombre de
documents		Descripteur
21Humans
21Nervous system diseases
20Parkinson disease
19Parkinson's disease
12Severity of Illness Index
11Recommendation
11rating scales
9Parkinson Disease (diagnosis)
9Psychometrics
9Questionnaires
8Reproducibility of Results
8clinimetrics
7Parkinson Disease (physiopathology)
6Parkinson Disease (complications)
6Parkinson Disease (drug therapy)
5Antiparkinson Agents (therapeutic use)
5Force
5Parkinson Disease (psychology)
4Reliability
4Treatment
4Validity
4psychometrics
4reliability
4validity
3Antiparkinson Agents (adverse effects)
3Depression
3Diagnostic and Statistical Manual of Mental Disorders
3Disability Evaluation
3Dopamine agonist
3Dyskinesia
3Evaluation Studies as Topic
3Evaluation scale
3Evidence-based medicine
3Movement Disorders (diagnosis)
3Parkinson Disease (epidemiology)
3Psychometrics (standards)
3depression
3dopamine agonists
3evidence‐based medicine
2Adult
2Amantadine
2Amine oxidase (flavin-containing)
2Clinical trial
2Deep brain stimulation
2Dyskinesias (drug therapy)
2Dystonia (diagnosis)
2Evidence-Based Medicine
2Female
2Health Planning Guidelines
2Health Status
2History, 20th Century
2Levodopa
2Male
2Middle Aged
2Motor system disorder
2Myelodysplastic syndrome
2Organic Chemicals (adverse effects)
2Organic Chemicals (therapeutic use)
2Parkinson Disease (surgery)
2Parkinson Disease (therapy)
2Placebo
2Prevalence
2Prognosis
2Psychiatric Status Rating Scales (standards)
2Psychometrics (methods)
2PubMed (statistics & numerical data)
2Questionnaires (standards)
2Randomized Controlled Trials as Topic
2Revision
2Sarizotan
2Treatment Outcome
2amantadine
2anticholinergics
2deep brain stimulation
2dyskinesias
2levodopa
2monoamine oxidase inhibitors
2neurosurgery
2randomized clinical trials
2sarizotan
1Acupuncture
1Acupuncture Therapy
1Advisory Committees
1Advisory Committees (standards)
1Aged
1Aged, 80 and over
1Amantadine (therapeutic use)
1Anhedonia
1Animal
1Animals
1Antiparkinson Agents (administration & dosage)
1Antiparkinson Agents (classification)
1Anxiety
1Anxiety Disorders (diagnosis)
1Anxiety Disorders (etiology)
1Apathy
1Apomorphine (therapeutic use)
1Autonomic Nervous System Diseases (drug therapy)
1Autonomic Nervous System Diseases (etiology)
1Basal Ganglia (drug effects)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Christopher G. Goetz" 

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Christopher G. Goetz" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Christopher G. Goetz
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024